Prolactin secretion in women: narrative review

F. Pérez-López, M. T. López-Baena, G. Pérez-Roncero
{"title":"Prolactin secretion in women: narrative review","authors":"F. Pérez-López, M. T. López-Baena, G. Pérez-Roncero","doi":"10.21037/GPM-21-4","DOIUrl":null,"url":null,"abstract":"The aim of this review is to explore relevant aspects of prolactin physiology and the conditions associated with hyperprolactinemia in women. PubMed and Google Scholar were queried using pertinent keywords to retrieve relevant studies with a particular focus on prolactin physiology, hyperprolactinemia, macroprolactinemia, prolactinoma, and general conditions that may displays alterations of prolactin secretion. Circulating prolactin displays a circadian cycle that disappears during pregnancy, hyperprolactinemia, and prolactinoma. Prolactin is under dopaminergic control and the influence of estrogens during reproductive years. Physical activity is a powerful stimulus for the pituitary release of prolactin. During pregnancy circulating prolactin increases and is present in the amniotic fluid. During lactation, the principal stimulus for prolactin secretion is breast suckling. Hyperprolactinemia may be related to functional causes or due to the presence of tumors producing prolactin (prolactinoma). Hyperprolactinemia may correspond to excessive production of normal (monomeric) prolactin or polymeric molecules (macroprolactinemia). The use of polyethylene glycol may differentiate the presence of those forms of prolactin. Functional hyperprolactinemia may be treated with dopaminergic agents like bromocriptine or cabergoline. The majority of cases of hyperprolactinemia associated with pituitary tumors correspond to microprolactinomas that may be treated with the same drugs. Macroprolactinoma may be treated with the same compounds, although surgical excision may be needed in some cases. These drugs should be interrupted during pregnancy unless prolactinoma grows or expand out of the sella turcica. A prolactin fragment has been related to the rare peripartum cardiomyopathy that appears during the last month of pregnancy or within the initial five months after delivery. Hyperprolactinemia has been also associated with an increased risk of subclinical atherosclerosis.","PeriodicalId":92781,"journal":{"name":"Gynecology and pelvic medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and pelvic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/GPM-21-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of this review is to explore relevant aspects of prolactin physiology and the conditions associated with hyperprolactinemia in women. PubMed and Google Scholar were queried using pertinent keywords to retrieve relevant studies with a particular focus on prolactin physiology, hyperprolactinemia, macroprolactinemia, prolactinoma, and general conditions that may displays alterations of prolactin secretion. Circulating prolactin displays a circadian cycle that disappears during pregnancy, hyperprolactinemia, and prolactinoma. Prolactin is under dopaminergic control and the influence of estrogens during reproductive years. Physical activity is a powerful stimulus for the pituitary release of prolactin. During pregnancy circulating prolactin increases and is present in the amniotic fluid. During lactation, the principal stimulus for prolactin secretion is breast suckling. Hyperprolactinemia may be related to functional causes or due to the presence of tumors producing prolactin (prolactinoma). Hyperprolactinemia may correspond to excessive production of normal (monomeric) prolactin or polymeric molecules (macroprolactinemia). The use of polyethylene glycol may differentiate the presence of those forms of prolactin. Functional hyperprolactinemia may be treated with dopaminergic agents like bromocriptine or cabergoline. The majority of cases of hyperprolactinemia associated with pituitary tumors correspond to microprolactinomas that may be treated with the same drugs. Macroprolactinoma may be treated with the same compounds, although surgical excision may be needed in some cases. These drugs should be interrupted during pregnancy unless prolactinoma grows or expand out of the sella turcica. A prolactin fragment has been related to the rare peripartum cardiomyopathy that appears during the last month of pregnancy or within the initial five months after delivery. Hyperprolactinemia has been also associated with an increased risk of subclinical atherosclerosis.
女性催乳素分泌:叙事回顾
本综述的目的是探讨催乳素生理学的相关方面和与女性高催乳素血症相关的条件。使用相关关键词查询PubMed和谷歌Scholar检索相关研究,特别关注催乳素生理学、高催乳素血症、巨催乳素血症、催乳素瘤以及可能显示催乳素分泌改变的一般情况。循环催乳素显示一个昼夜周期,在怀孕、高催乳素血症和催乳素瘤期间消失。在生育年龄,催乳素受多巴胺能控制和雌激素的影响。体育活动是垂体释放催乳素的有力刺激。在怀孕期间循环催乳素增加,存在于羊水中。在哺乳期,催乳素分泌的主要刺激是母乳喂养。高催乳素血症可能与功能性原因或由于产生催乳素的肿瘤(催乳素瘤)的存在有关。高催乳素血症可能对应于正常(单体)催乳素或聚合分子(大催乳素血症)的过量产生。聚乙二醇的使用可以区分这些形式的催乳素的存在。功能性高催乳素血症可用多巴胺能药物如溴隐亭或卡麦角林治疗。大多数与垂体肿瘤相关的高催乳素血症病例对应的微催乳素瘤可以用相同的药物治疗。巨催乳素瘤可以用相同的化合物治疗,尽管在某些情况下可能需要手术切除。这些药物应在怀孕期间中断,除非催乳素瘤生长或扩大到蝶鞍以外。催乳素片段与罕见的围产期心肌病有关,这种病出现在妊娠的最后一个月或分娩后的最初五个月内。高催乳素血症也与亚临床动脉粥样硬化的风险增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信